Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Sverige |
---|---|
Lista | Spotlight |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
EQL Pharma has today purchased seven (7) licenses, of which five (5) are exclusive, for products on the Danish market. The licenses already have marketing authorizations in Denmark. "These are niche generics that complement our portfolio well and fit into our strategy for the Nordic region and Denmark," says Christer Fåhraeus, CEO of EQL Pharma. The total turnover in the markets where these products compete is slightly more than 50mDKK (2020). All products are prescription-only and have between one and three active competitors, excluding EQL.
The sales start is expected in EQL Pharma's first financial quarter 2021/22. "With this type of in-licensing, where the marketing authorization already exists, and we take over an existing stock, the market introduction takes place very rapidly and the competitive landscape is therefore well defined. In general, the price tag for in-licensing and purchasing of existing marketing authorizations are in the same order of magnitude as in-house development of niche products for the Nordic region", says Christer Fåhraeus.
This disclosure contains information that EQL Pharma is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 15-03-2021 15:10 CET.